Cargando…

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

BACKGROUND: Cytomegalovirus (CMV) infection is a serious complication following heart transplantation. This study (June 2003–January 2010) retrospectively assessed the effects of oral valganciclovir prophylaxis in adult heart transplant recipients during the first year after transplantation. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doesch, Andreas O, Repp, Janika, Hofmann, Nina, Erbel, Christian, Frankenstein, Lutz, Gleissner, Christian A, Schmidt, Constanze, Ruhparwar, Arjang, Zugck, Christian, Schnitzler, Paul, Ehlermann, Philipp, Dengler, Thomas J, Katus, Hugo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472651/ https://www.ncbi.nlm.nih.gov/pubmed/23091373 http://dx.doi.org/10.2147/DDDT.S36578

Ejemplares similares

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study
por: Doesch, Andreas O, et al.
Publicado: (2013)

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation
por: Gueler, Ibrahim, et al.
Publicado: (2013)

Conversion to generic cyclosporine A in stable chronic patients after heart transplantation
por: Kraeuter, Maximilian, et al.
Publicado: (2013)

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
por: Doesch, Andreas O, et al.
Publicado: (2013)

Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation
por: Helmschrott, Matthias, et al.
Publicado: (2015)

Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
por: Rivinius, Rasmus, et al.
Publicado: (2014)

Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2016)

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
por: Helmschrott, Matthias, et al.
Publicado: (2014)

The influence of surgical technique on early posttransplant atrial fibrillation – comparison of biatrial, bicaval, and total orthotopic heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2017)

Inhibition of B7-1 (CD80) by RhuDex(®) reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions
por: Doesch, Andreas O, et al.
Publicado: (2014)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

Adjuvant Use of Ivabradine in Acute Heart Failure due to Myocarditis
por: Franke, Jennifer, et al.
Publicado: (2011)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival
por: Rivinius, Rasmus, et al.
Publicado: (2018)

Elevated pre‐transplant pulmonary vascular resistance is associated with early post‐transplant atrial fibrillation and mortality
por: Rivinius, Rasmus, et al.
Publicado: (2020)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure
por: Franke, Jennifer, et al.
Publicado: (2015)

Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality
por: Rivinius, Rasmus, et al.
Publicado: (2017)

CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions
por: Akhavanpoor, Mohammadreza, et al.
Publicado: (2014)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

CXCL4 Plasma Levels Are Not Associated with the Extent of Coronary Artery Disease or with Coronary Plaque Morphology
por: Erbel, Christian, et al.
Publicado: (2015)

Adventitial inflammation and its interaction with intimal atherosclerotic lesions
por: Akhavanpoor, Mohammadreza, et al.
Publicado: (2014)

Inflammatory therapeutic targets in coronary atherosclerosis—from molecular biology to clinical application
por: Linden, Fabian, et al.
Publicado: (2014)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Systematic RNA-interference in primary human monocyte-derived macrophages: A high-throughput platform to study foam cell formation
por: Domschke, Gabriele, et al.
Publicado: (2018)

Constrictive Pericarditis in the Presence of Remaining Remnants of a Left Ventricular Assist Device in a Heart Transplanted Patient
por: Rivinius, R., et al.
Publicado: (2015)

Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2017)

Haemodynamic effects of percutaneous mitral valve edge‐to‐edge repair in patients with end‐stage heart failure awaiting heart transplantation
por: Geis, Nicolas A., et al.
Publicado: (2018)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
por: Ehlermann, Philipp, et al.
Publicado: (2008)

Transfemoral aortic valve replacement for severe aortic valve regurgitation in a patient with a pulsatile‐flow biventricular assist device
por: Gomes, Bruna, et al.
Publicado: (2018)

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
por: Torii, Yuka, et al.
Publicado: (2023)

PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels
por: Erbel, C, et al.
Publicado: (2011)

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p9egv5eaqq5iu4tcr63kuqa8si